V940
intismeran autogene
PHASE3
Drug Profile
ModalitymRNA
RouteIM
Therapy AreaOncology
Peak Sales Est$6000M
Formulations[]
Companies
MRNA (CO_DEVELOPER)50%
Mechanism: mRNA neoantigen vaccine
Expert: Personalized mRNA cancer vaccine targeting tumor neoantigens
Everyday: Trains immune system to attack patient-specific cancer proteins
Targets: []
Programs (2)
Upcoming Catalysts (1)
V940 - Melanoma - Ph3 - Interim (INTerpath-001)
H2 2026
Notes
Personalized mRNA cancer vaccine. Partnered with Moderna. Phase 3 KEYNOTE-942 in melanoma with Keytruda.
Data from Supabase · Updated 2026-03-24